BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Capital Expenditures data on file, last reported at $69000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $69000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 380.29% YoY), and the FY2025 full-year result was $1.1 million, up 293.19% from the prior year.
• Capital Expenditures slipped to $69000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.8 million in Q4 2022 to a low of -$3.2 million in Q3 2022.
• A 5-year average of $424400.0 and a median of $69000.0 in 2026 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 246.03% in 2024 and jumped 21600.0% in 2025, its largest moves.
• Tracing BBIO's Capital Expenditures over 5 years: stood at $4.8 million in 2022, then plunged by 101.93% to -$92000.0 in 2023, then surged by 105.43% to $5000.0 in 2024, then jumped by 21600.0% to $1.1 million in 2025, then plunged by 93.64% to $69000.0 in 2026.
• Business Quant data shows BBIO's Capital Expenditures at $69000.0 in Q1 2026, $1.1 million in Q4 2025, and $12000.0 in Q3 2025.